Symlin titration trial
Executive Summary
Amylin is in discussions with FDA to design a dose titration study of Symlin (pramlintide) in patients with type 1 diabetes following an FDA advisory committee request for additional safety data, the company said during a teleconference Sept. 19. The company expects a decision on pramlintide in early October